Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;9(1):5-18.
doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

Clinical Goals and Barriers to Effective Psoriasis Care

Bruce E Strober  1   2 , Joelle M van der Walt  3 , April W Armstrong  4 , Marc Bourcier  5 , Andre V E Carvalho  6 , Edgardo Chouela  7 , Arnon D Cohen  8   9 , Claudia de la Cruz  10 , Charles N Ellis  11 , Andrew Y Finlay  12 , Alice B Gottlieb  13 , Johann E Gudjonsson  11 , Lars Iversen  14 , C Elise Kleyn  15 , Craig L Leonardi  16 , Charles W Lynde  17 , Caitriona Ryan  18 , Colin T Theng  19 , Fernando Valenzuela  20 , Ronald Vender  21 , Jashin J Wu  22 , Helen S Young  15 , Alexa B Kimball  23
Affiliations

Clinical Goals and Barriers to Effective Psoriasis Care

Bruce E Strober et al. Dermatol Ther (Heidelb). 2019 Mar.

Abstract

Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the treatment goals of psoriasis patients and worldwide barriers to optimal care. Setting clear expectations might ultimately encourage undertreated psoriasis patients to seek care in an era in which great gains in therapeutic efficacy have been achieved. Here, we discuss the option for early treatment of all categories of psoriasis to alleviate disease impact while emphasizing the need for more focused attention for psoriasis patients with mild and moderate forms of this autoimmune disease. In addition, we encourage policy changes to keep pace with the innovative therapies and clinical science and highlight the demand for greater understanding of treatment barriers in resource-poor countries.

Keywords: Body surface area; Clearance; Comorbidities; DLQI; Itch; PASI; Physician Global Assessment; Psoriasis.

PubMed Disclaimer

References

    1. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. doi: 10.4414/smw.2014.13968. - DOI - PubMed
    1. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185. doi: 10.1001/jamadermatol.2013.5264. - DOI - PubMed
    1. van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–2010. doi: 10.1111/jdv.13150. - DOI - PMC - PubMed
    1. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. doi: 10.1007/s40257-015-0169-x. - DOI - PMC - PubMed
    1. Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2016 doi: 10.1007/s13555-016-0153-2. - DOI - PMC - PubMed